Skip to content

Study · Not a test of the peptide alone · 1987

3 results

On the molecular size of thymosins.

Haritos AA, Yialouris PP, Heimer EP, Felix AM, Rosemeyer MA

FEBS letters1 Jun 1987Cited by 15 (Europe PMC)

PMID3595856 (opens in a new tab)DOI10.1016/0014-5793(87)81028-1 (opens in a new tab)PepBankPUB-03595856
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Other

    In gel-filtration measurements, prothymosin alpha and its N-terminal fragment thymosin alpha 1m behaved as oligomers (trimers to hexamers).

    In plain wordsIn lab tests, prothymosin alpha and its fragment thymosin alpha 1m appeared to form groups of three to six molecules.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableOligomeric state in gel filtration
    Study

    n: not reported in source

    in vitro biophysical measurements
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    relative molecular mass
    3108
    thymosin alpha 1m

    Source sentences

    Summary
    The immunoregulatory polypeptide prothymosin alpha and its biologically active N-terminal fragment thymosin alpha 1m, with relative molecular masses of 12,500 and 3108 respectively, were found to behave as oligomers (trimers to hexamers) in gel-filtration measurements.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Other

    Sedimentation equilibrium ultracentrifugation showed that thymosin alpha‑1 is a monomer with a relative molecular mass of 3000 +/- 200.

    In plain wordsIn lab tests, thymosin alpha‑1 was a single molecule, not a cluster.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableOligomeric state by sedimentation equilibrium ultracentrifugation
    Study

    n: not reported in source

    in vitro biophysical measurements
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    relative molecular mass
    3000
    sedimentation equilibrium

    Source sentences

    Summary
    In contrast, sedimentation equilibrium ultracentrifugation shows that thymosin alpha 1 is a monomer with a relative molecular mass of 3000 +/- 200.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Other

    The measured diffusion coefficient of thymosin alpha‑1 was 221 micron2/s, which suggests an approximately spherical molecule.

    In plain wordsIn lab tests, thymosin alpha‑1 had a diffusion rate that suggests a roughly round shape.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableDiffusion coefficient and molecular shape
    Study

    n: not reported in source

    in vitro biophysical measurements
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    diffusion coefficient
    221 micron2/s
    thymosin alpha 1

    Source sentences

    Summary
    Measurement of the diffusion coefficient as 221 micron2/s suggests that the molecule is approximately spherical.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 18:17 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    10 Oct 2026, 08:55 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.